Molecule
Lacosamide is a prescription medicine indicated for treatment of partial-onset seizures in patients 1 month of age and older, among other approved uses. It is available as tablets, oral solution and injection for intravenous use. MedsAcross supplies Lacosamide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
VIMPAT is indicated for: Treatment of partial-onset seizures in patients 1 month of age and older. Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older
Source: US FDA prescribing information
The precise mechanism by which VIMPAT exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.
Source: US FDA prescribing information
Adults (17 years and older): Initial dosage for monotherapy for the treatment of partial-onset seizures is 100 mg twice daily. Initial dosage for adjunctive therapy for the treatment of partial-onset seizures or primary generalized tonic-clonic seizures is 50 mg twice daily. Maximum recommended dosage for monotherapy and adjunctive therapy is 200 mg twice daily. Pediatric Patients 1 month to less than 17 years: The recommended dosage is based on body weight and is administered orally twice daily. Increase dosage based on clinical response and tolerability, no more frequently than once per week. Injection: for intravenous use only when oral administration is temporarily not feasible, the recommended dosage is based on body weight and is administered two or three times daily over 15 to 60 minutes, obtaining ECG before initiation is recommended in certain patients.
Source: US FDA prescribing information
None. None
Source: US FDA prescribing information
Monitor patients for suicidal behavior and ideation. VIMPAT may cause dizziness and ataxia. Cardiac Rhythm and Conduction Abnormalities: Obtaining ECG before beginning and after titration to steady-state maintenance is recommended in patients with underlying proarrhythmic conditions or on concomitant medications that affect cardiac conduction, closely monitor these patients. VIMPAT may cause syncope. VIMPAT should be gradually withdrawn to minimize the potential of increased seizure frequency. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/ Multi-Organ Hypersensitivity: Discontinue if no alternate etiology
Source: US FDA prescribing information
The following serious adverse reactions are described below and elsewhere in the labeling: Suicidal Behavior and Ideation Dizziness and Ataxia Cardiac Rhythm and Conduction Abnormalities Syncope Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Reactions Adjunctive therapy: Most common adverse reactions in adults (≥10% and greater than placebo) are diplopia, headache, dizziness, nausea, and somnolence. Monotherapy: Most common adverse reactions are similar to those seen in adjunctive therapy studies. Pediatric patients: Adverse reactions are similar to those seen in adult patients
Source: US FDA prescribing information
Strong CYP3A4 or CYP2C9 Inhibitors Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to VIMPAT. Dose reduction may be necessary in these patients.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F). Do not freeze VIMPAT injection or oral solution.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
15 presentations of Lacosamide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Lacosamide 50 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lacosamide 100 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lacosamide 200 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lacosamide 150 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lacosamide 10 mg/mL oral solutionOralGeneric name | — | US FDA | Available on request |
| Lacosamide 200 mg/20 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Vimpat 100 mg tabletOral | UCB | US FDA | Available on request |
| Vimpat 150 mg tabletOral | UCB | US FDA | Available on request |
| Vimpat 200 mg tabletOral | UCB | US FDA | Available on request |
| Vimpat 50 mg tabletOral | UCB | US FDA | Available on request |
| Motpoly XR 100 mg extended-release capsuleOral | Aucta Pharmaceuticals | US FDA | Available on request |
| Motpoly XR 150 mg extended-release capsuleOral | Aucta Pharmaceuticals | US FDA | Available on request |
| Motpoly XR 200 mg extended-release capsuleOral | Aucta Pharmaceuticals | US FDA | Available on request |
| Vimpat 10 mg/mL oral solutionOral | UCB | US FDA | Available on request |
| Vimpat 200 mg/20 mL injectionIntravenous | UCB | US FDA | Available on request |
2 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Lacosamide in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 15 presentations of Lacosamide and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Lacosamide, including Motpoly XR, Vimpat.
Yes. The US FDA first approved Lacosamide on 28 October 2008, according to Drugs@FDA.
Yes. Lacosamide has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Lacosamide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Lacosamide is classified under ATC code N03AX18 (Lacosamide).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.